An open, randomized controlled study comparing the efficacy of Rikang Trastuzumab combined with radiotherapy versus Rikang Trastuzumab monotherapy in patients with HER2-positive advanced breast cancer with brain metastases.

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: 5bc829e73273e4bbde7dff2060a064516b0d3030
First added on: Apr 23, 2026